These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11712769)

  • 1. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors.
    Pepine CJ; Handberg EM
    Clin Cardiol; 2001 Nov; 24(11 Suppl):V1-5. PubMed ID: 11712769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the renin-angiotensin system in vascular health: use of ACE inhibition to improve vascular function.
    Izzo JL
    Heart Dis; 2000; 2(5):380-3. PubMed ID: 11728286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function.
    Neutel JM
    J Hum Hypertens; 2004 Sep; 18(9):599-606. PubMed ID: 15190263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial dysfunction: its pathogenic role in atherosclerosis and its reversal by ACE inhibition.
    Neutel JM
    Postgrad Med; 2000 Oct; 108(5 Suppl):4-11. PubMed ID: 19667535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin angiotensin system and ASCVD.
    Farmer JA
    Curr Opin Cardiol; 2000 May; 15(3):141-50. PubMed ID: 10952419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular renin-angiotensin-system, endothelial function and atherosclerosis?
    Holtz J; Goetz RM
    Basic Res Cardiol; 1994; 89 Suppl 1():71-86. PubMed ID: 7945178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond blood pressure: the endothelium and atherosclerosis progression.
    Schiffrin EL;
    Am J Hypertens; 2002 Oct; 15(10 Pt 2):115S-122S. PubMed ID: 12383592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
    Higashi Y; Chayama K; Yoshizumi M
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):133-48. PubMed ID: 15853700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of angiotensin II receptor blockers in animal models of atherosclerosis.
    Ferrario CM
    Am J Hypertens; 2002 Jan; 15(1 Pt 2):9S-13S. PubMed ID: 11824874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular interactions of vasoactive systems in cardiovascular damage.
    Bader M
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S7-9. PubMed ID: 11811382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
    Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P
    J Am Coll Cardiol; 1998 Nov; 32(5):1228-37. PubMed ID: 9809930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection?
    Ferrari R
    J Hypertens Suppl; 1997 Mar; 15(2):S109-17. PubMed ID: 9218207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical insights into the beneficial and protective actions of the kallikrein-kinin system.
    Regoli D; Gobeil F
    Vascul Pharmacol; 2015 Jan; 64():1-10. PubMed ID: 25579779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular protection: current possibilities and future perspectives.
    Lüscher TF
    Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.